Company & Sponsor Intelligence

Eli Lilly and Company

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials47

Recruiting7

Completed35

Countries10

Therapeutic footprint

adhdalzheimersdepressionmigraine_headacheneuro_oncologyother_psychiatrypain_neuropathyparkinsonsschizophrenia

Indexed studies

NCT01807026A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease
alzheimers · United StatesPHASE1

NCT01237587A Study of Duloxetine in Adolescents With Juvenile Primary Fibromyalgia Syndrome
pain_neuropathy · United StatesPHASE3

NCT00485875Safety and Efficacy of Switching From a Stimulant Medication to Atomoxetine in Children and Adolescents With ADHD
adhd · United StatesPHASE4

NCT00546910Comparison of Atomoxetine Versus Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
adhd · GermanyPHASE4

NCT00190957Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse
adhd · United StatesPHASE4

NCT00485771Olanzapine/Fluoxetine Combination Versus Comparator in the Treatment of Bipolar I Depression
depression · United StatesPHASE4

NCT02008357Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
other_psychiatry · United StatesPHASE3

NCT00191659Study of Broader Efficacy of Atomoxetine in the Treatment of ADHD in Children/Adolescents
adhd · United KingdomPHASE3

NCT07142954Epidemiology and Biomarker Study in Alzheimer's Disease
alzheimers · United StatesPHASE3

NCT06809400A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
parkinsons · United StatesPHASE1

NCT00904683Effect of LY2062430 on the Progression of Alzheimer's Disease
alzheimers · United StatesPHASE3

NCT00666757A Study Comparing Duloxetine to Other Antidepressants in the Treatment of Severe Depression
depression · United StatesPHASE4

Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →